Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations.


Journal

Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 08 01 2019
accepted: 13 03 2019
pubmed: 4 4 2019
medline: 1 4 2021
entrez: 4 4 2019
Statut: ppublish

Résumé

Our aim was to evaluate correlation between clinicopathological features (clinical T and clinical N stages; histological type; nuclear grade; hormone-receptor and HER2 status, proliferation activity and tumor subtypes) of breast cancer and kinetic parameters measured by staging dynamic FDG-PET/CT examinations. Following ethical approval and patients' informed consent we included 34 patients with 35 primary breast cancers in our prospective study. We performed dynamic PET imaging, and assessed plasma activity noninvasively. To delineate primary tumors we applied a frame-by-frame semi-automatic software-based correction of motion artefacts. FDG two-compartment kinetic modelling was applied to assess K1, k2, k3 rate coefficients and to calculate Ki (tracer flux constant) and MRFDG (FDG metabolic rate). We found that k3, Ki and MRFDG were significantly higher in higher grade (p = 0.0246, 0.0089 and 0.0076, respectively), progesterone-receptor negative (p = 0.0344, 0.0217 and 0.0132) and highly-proliferating (p = 0.0414, 0.0193 and 0.0271) tumors as well as in triple-negative and hormone-receptor negative/HER2-positive subtypes (p = 0.0310, 0.0280 and 0.0186). Ki and MRFDG were significantly higher in estrogen-receptor negative tumors (p = 0.0300 and 0.0247, respectively). Ki was significantly higher in node-positive than in node-negative disease (p = 0.0315). None of the assessed FDG-kinetic parameters showed significant correlation with stromal TIL. In conclusion, we confirmed a significant relationship between kinetic parameters measured by dynamic PET and the routinely assessed clinicopathological factors of breast cancer: high-grade, hormone-receptor negative tumors with high proliferation rate are characterized by higher cellular FDG-uptake and FDG-phosphorylation rate. Furthermore, we found that kinetic parameters based on the dynamic examinations are probably not influenced by stromal TIL infiltration.

Identifiants

pubmed: 30941738
doi: 10.1007/s12253-019-00641-0
pii: 10.1007/s12253-019-00641-0
pmc: PMC7242263
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

997-1006

Références

J Magn Reson Imaging. 2010 Nov;32(5):1124-31
pubmed: 21031518
J Nucl Med. 2002 Apr;43(4):500-9
pubmed: 11937594
J Nucl Med. 2004 Nov;45(11):1829-37
pubmed: 15534051
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
J Clin Pathol. 2015 Apr;68(4):274-82
pubmed: 25595275
Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61
pubmed: 27251642
J Clin Pathol. 2013 Jun;66(6):512-6
pubmed: 23436927
Clin Cancer Res. 2011 Apr 15;17(8):2400-9
pubmed: 21364034
J Clin Oncol. 2008 Sep 20;26(27):4449-57
pubmed: 18626006
J Clin Oncol. 2007 Jan 1;25(1):118-45
pubmed: 17159189
J Nucl Med. 2007 Jun;48(6):932-45
pubmed: 17504879
Acad Radiol. 2008 Oct;15(10):1246-54
pubmed: 18790395
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200
pubmed: 19915839
Phys Med Biol. 2017 May 7;62(9):3639-3655
pubmed: 28191877
Radiology. 2013 Feb;266(2):388-405
pubmed: 23220901
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Clin Cancer Res. 2005 Apr 15;11(8):2785-808
pubmed: 15837727
J Nucl Med. 2007 Jun;48(6):920-5
pubmed: 17504870
Nucl Med Biol. 2000 Oct;27(7):643-6
pubmed: 11091106
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
J Gastric Cancer. 2017 Dec;17(4):384-393
pubmed: 29302378
J Nucl Med. 2006 Jun;47(6):1059-66
pubmed: 16741317
Nucl Med Commun. 2015 Jan;36(1):28-37
pubmed: 25299471
Anticancer Res. 2018 Aug;38(8):4927-4931
pubmed: 30061271
Mod Pathol. 1998 Feb;11(2):155-68
pubmed: 9504686

Auteurs

Kornélia Kajáry (K)

Pozitron PET/CT Center, Hunyadi J. Str. 9, Budapest, H-1117, Hungary.

Zsolt Lengyel (Z)

Pozitron PET/CT Center, Hunyadi J. Str. 9, Budapest, H-1117, Hungary.

Anna-Mária Tőkés (AM)

Semmelweis University 2nd Department of Pathology, Üllői str. 93., Budapest, H-1091, Hungary.

Janina Kulka (J)

Semmelweis University 2nd Department of Pathology, Üllői str. 93., Budapest, H-1091, Hungary.

Magdolna Dank (M)

Semmelweis University Oncology Center, Tömő utca 25-29, 4th floor, Budapest, H-1083, Hungary.

Tímea Tőkés (T)

Semmelweis University Oncology Center, Tömő utca 25-29, 4th floor, Budapest, H-1083, Hungary. tokes.timea@med.semmelweis-univ.hu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH